Personalis (PSNL) Scheduled to Post Quarterly Earnings on Wednesday

Personalis (NASDAQ:PSNL) will be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Personalis has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. The company had revenue of $19.68 million for the quarter, compared to analysts’ expectations of $19.56 million. On average, analysts expect Personalis to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Down 3.8 %

PSNL opened at $1.54 on Monday. Personalis has a twelve month low of $0.89 and a twelve month high of $2.60. The company has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $1.44.

Analyst Ratings Changes

Several brokerages have commented on PSNL. Lake Street Capital initiated coverage on shares of Personalis in a research report on Tuesday, April 30th. They set a “buy” rating and a $4.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $3.50 target price on shares of Personalis in a research report on Thursday, April 11th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.